For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
10
views
99
references
 Top references
cited by
27
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      837
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Preferentially expressed antigen in melanoma (PRAME), which belongs to the cancer/testis antigen (CTA) gene family, plays a pivotal role in multiple cellular processes and immunotherapy response in human cancers. PRAME is highly expressed in different types of cancers and is involved in cell proliferation, apoptosis, differentiation and metastasis as well as the outcomes of patients with cancer. In this review article, we discuss the potential roles and physiological functions of PRAME in various types of cancers. Moreover, this review highlights immunotherapeutic strategies that target PRAME in human malignancies. Therefore, the modulation of PRAME might be useful for the treatment of patients with cancer.

          Related collections

          Most cited references99

          • Record: found
          • Abstract: found
          • Article: not found

          Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial

          Breelyn Wilky, Matteo Trucco, Ty K Subhawong … (2019)
          VEGF promotes an immunosuppressive microenvironment and contributes to immune checkpoint inhibitor resistance in cancer. We aimed to assess the activity of the VEGF receptor tyrosine-kinase inhibitor axitinib plus the anti-PD-1 immune checkpoint inhibitor pembrolizumab in patients with sarcoma.
          Article 0 comments Cited 163 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Gene expression changes associated with progression and response in chronic myeloid leukemia.

            Brian J Druker, Mao An, Charles Sawyers … (2006)
            Chronic myeloid leukemia (CML) is a hematopoietic stem cell disease with distinct biological and clinical features. The biologic basis of the stereotypical progression from chronic phase through accelerated phase to blast crisis is poorly understood. We used DNA microarrays to compare gene expression in 91 cases of CML in chronic (42 cases), accelerated (17 cases), and blast phases (32 cases). Three thousand genes were found to be significantly (P < 10(-10)) associated with phase of disease. A comparison of the gene signatures of chronic, accelerated, and blast phases suggest that the progression of chronic phase CML to advanced phase (accelerated and blast crisis) CML is a two-step rather than a three-step process, with new gene expression changes occurring early in accelerated phase before the accumulation of increased numbers of leukemia blast cells. Especially noteworthy and potentially significant in the progression program were the deregulation of the WNT/beta-catenin pathway, the decreased expression of Jun B and Fos, alternative kinase deregulation, such as Arg (Abl2), and an increased expression of PRAME. Studies of CML patients who relapsed after initially successful treatment with imatinib demonstrated a gene expression pattern closely related to advanced phase disease. These studies point to specific gene pathways that might be exploited for both prognostic indicators as well as new targets for therapy.
            Article 0 comments Cited 146 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor.

              Hideyuki Ikeda, Bernard Lethé, Frederic Lehmann … (1997)
              Melanoma lines MEL.A and MEL.B were derived from metastases removed from patient LB33 in 1988 and 1993, respectively. The MEL.A cells express several antigens recognized by autologous cytolytic T lymphocytes (CTL) on HLA class I molecules. The MEL.B cells have lost expression of all class I molecules except for HLA-A24. By stimulating autologous lymphocytes with MEL.B, we obtained an HLA-A24-restricted CTL clone that lysed these cells. A novel gene, PRAME, encodes the antigen. It is expressed in a large proportion of tumors and also in some normal tissues, albeit at a lower level. Surprisingly, the CTL failed to lyse MEL.A, even though these cells expressed the gene PRAME. The CTL expresses an NK inhibitory receptor that inhibits its lytic activity upon interaction with HLA-Cw7 molecules, which are present on MEL.A cells and not on MEL.B. Such CTL, active against tumor cells showing partial HLA loss, may constitute an intermediate line of anti-tumor defense between the CTL, which recognize highly specific tumor antigens, and the NK cells, which recognize HLA loss variants.
              Article 0 comments Cited 132 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Contributors
                Zhi‐wei Wang:
                ORCID: https://orcid.org/0000-0002-6465-7779
                zwang6@bidmc.harvard.edu , zhiweichina@126.com
                Xueqiong Zhu:
                ORCID: https://orcid.org/0000-0002-8389-928X
                zjwzzxq@163.com
                Journal
                Journal ID (nlm-ta): Cell Prolif
                Journal ID (iso-abbrev): Cell Prolif
                Journal ID (doi): 10.1111/(ISSN)1365-2184
                Journal ID (publisher-id): CPR
                Title: Cell Proliferation
                Publisher: John Wiley and Sons Inc. (Hoboken )
                ISSN (Print): 0960-7722
                ISSN (Electronic): 1365-2184
                Publication date (Electronic): 05 February 2020
                Publication date Collection: March 2020
                Volume: 53
                Issue: 3 ( doiID: 10.1111/cpr.v53.3 )
                Electronic Location Identifier: e12770
                Affiliations
                [ 1 ] Departmant of Obstetrics and Gynecology The Second Affiliated Hospital of Wenzhou Medical University Wenzhou China
                [ 2 ] Department of Pathology Beth Israel Deaconess Medical Center Harvard Medical School Boston MA USA
                Author notes
                [*] [* ] Correspondence

                Zhi‐wei Wang, Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA.

                Emails: zwang6@ 123456bidmc.harvard.edu ; zhiweichina@ 123456126.com

                Xueqiong Zhu, Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, No. 109 Xueyuan Xi Road, Wenzhou, Zhejiang 325027, China.

                Email: zjwzzxq@ 123456163.com

                Author information
                https://orcid.org/0000-0002-6465-7779
                https://orcid.org/0000-0002-8389-928X
                Article
                Publisher ID: CPR12770
                DOI: 10.1111/cpr.12770
                PMC ID: 7106952
                PubMed ID: 32022332
                SO-VID: b4b9c84d-1e72-4f92-9c01-99da491be3b4
                Copyright © © 2020 The Authors. Cell Proliferation Published by John Wiley & Sons Ltd.
                License:

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                Date received : 22 October 2019
                Date revision received : 01 January 2020
                Date accepted : 15 January 2020
                Page count
                Figures: 1, Tables: 1, Pages: 9, Words: 7327
                Categories
                Subject: Review
                Subject: Reviews
                Custom metadata
                source-schema-version-number 2.0
                cover-date March 2020
                details-of-publishers-convertor Converter:WILEY_ML3GV2_TO_JATSPMC version:5.7.8 mode:remove_FC converted:31.03.2020

                ScienceOpen disciplines: Cell biology
                Keywords: immunotherapy,oncogene,prame,proliferation,tumorigenesis
                Data availability:
                ScienceOpen disciplines: Cell biology
                Keywords: immunotherapy, oncogene, prame, proliferation, tumorigenesis

                Comments

                Comment on this article

                scite_

                Similar content837

                See all similar

                Cited by27

                See all cited by

                Most referenced authors1,531

                See all reference authors